![](https://2c717466dc25cd7041c9-8eeda6a8ca964cf210ed223dbc947813.ssl.cf2.rackcdn.com/260072-500441796-logo-png-100x39.png)
ORYZON reports financial results and corporate update for half-year ending June 30, 2024
Company granted an End-of-Phase II meeting with the FDA to discuss plans for a registrational Phase III trial with vafidemstat in Borderline Personality Disorder (BPD) Final data from PORTICO, global Phase IIb vafidemstat trial in BPD, scheduled as an oral …